Evid Based Med doi:10.1136/eb-2012-101059
  • Therapeutics
  • Systematic review with meta-analysis

Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis

  1. Terry A Jacobson
  1. Department of Medicine, Emory University, Atlanta, Georgia, USA
  1. Correspondence to: Dr Terry A Jacobson
    Department of Medicine, Emory University, Atlanta, GA 30303, USA; tjaco02{at}

Commentary on:


High-quality evidence suggests that chronic kidney disease (CKD) should now be considered a coronary heart disease (CHD) risk equivalent. Although statin therapy consistently reduces coronary events in the general population, the clinical benefits of lipid lowering in persons with CKD are less certain. Although multiple studies have shown possible benefit from statin therapy in early-stage CKD patients, there has been a recent concern that patients with more severe CKD, such as those on dialysis, do not seem to benefit.


The authors identified randomised controlled trials with statins from a previously published meta-analysis,1 and supplemented it with recent trials identified in EMBASE, the Cochrane Central Register of Controlled Trials and the Cochrane Renal Group's Specialised …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article